Publications by authors named "E Rassy"
Article Synopsis
- CDK4/6 inhibitors have greatly improved treatment for hormone receptor-positive breast cancer, but developing resistance to these drugs remains a significant issue with few guidelines for alternative treatments.
- Continuing CDK4/6 inhibition, possibly alongside endocrine therapy or new drugs, is an active area of research that may change treatment practices based on the results of ongoing clinical trials.
- Evidence suggests switching to a different CDK4/6 inhibitor after progression can have limited benefits, and current biomarker analyses for patient selection have been inconsistent, indicating that further research and validation are necessary before making this approach standard practice.
Article Synopsis
- Patients with high-risk hormone receptor-positive, HER2-negative breast cancer (HR+ BC) show a significant risk of relapse, prompting the need for additional treatment strategies.
- The study analyzed data from the CANcer TOxicities (CANTO) study, involving patients between 2012 and 2022, categorizing them based on various unfavorable features indicating high risk.
- Results indicated that most patients underwent (neo)adjuvant chemotherapy and endocrine therapy; however, many discontinued treatment due to adverse events, with a 5-year survival rate reflecting the need for ongoing management in this patient group.
New clinical trials in CUP and a novel paradigm in cancer classification.
Nat Rev Clin Oncol
December 2024